Expression of BRI-amyloid β peptide fusion proteins: A novel method for specific high-level expression of amyloid β peptides

P. A. Lewis; S. Piper; M. Baker; L. Onstead; M. P. Murphy; J. Hardy; R. Wang; E. McGowan; T. E. Golde

doi:10.1016/S0925-4439(01)00054-0

Expression of BRI-amyloid β peptide fusion proteins: A novel method for specific high-level expression of amyloid β peptides

P. A. Lewis, S. Piper, M. Baker, L. Onstead, M. P. Murphy, J. Hardy, R. Wang, E. McGowan, T. E. Golde

Producción científica: Article › revisión exhaustiva

32 Citas (Scopus)

Resumen

In order to develop transgenic animal models that selectively overexpress various Aβ peptides, we have developed a novel expression system that selectively expresses Aβ40 or Aβ42 in the secretory pathway. This system utilizes fusion constructs in which the sequence encoding the 23-amino-acid ABri peptide at the carboxyl terminus of the 266-amino-acid type 2 transmembrane protein BRI is replaced with a sequence encoding either Aβ40 or Aβ42. Constitutive processing of the resultant BRI-Aβ fusion proteins in transfected cells results in high-level expression and secretion of the encoded Aβ peptide. Significantly, expression of Aβ42 from the BRI-Aβ42 construct resulted in no increase in secreted Aβ40, suggesting that the majority of Aβ42 is not trimmed by carboxypeptidase to Aβ40 in the secretory pathway.

Idioma original	English
Páginas (desde-hasta)	58-62
Número de páginas	5
Publicación	Biochimica et Biophysica Acta - Molecular Basis of Disease
Volumen	1537
N.º	1
DOI	https://doi.org/10.1016/S0925-4439(01)00054-0
Estado	Published - jul 27 2001

Nota bibliográfica

Funding Information:
This work was supported by a Beeson Award from AFAR, an Ellison Medical Foundation New Scholars award and the NIH (NS39072, T.E.G.) (AG10491, R.W.) (Mayo Clinic ADRC, J.H.). BC05, BAN50, and BA27 were gifts of Takeda Industries.

Financiación

This work was supported by a Beeson Award from AFAR, an Ellison Medical Foundation New Scholars award and the NIH (NS39072, T.E.G.) (AG10491, R.W.) (Mayo Clinic ADRC, J.H.). BC05, BAN50, and BA27 were gifts of Takeda Industries.

Financiadores	Número del financiador
National Institutes of Health (NIH)	AG10491
National Institute of Neurological Disorders and Stroke	R01NS039072
Ellison Medical Foundation
Mayo Clinic Rochester
American Federation for Aging Research

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

Acceder al documento

10.1016/S0925-4439(01)00054-0

Otros archivos y enlaces

Citar esto

Lewis, P. A., Piper, S., Baker, M., Onstead, L., Murphy, M. P., Hardy, J., Wang, R., McGowan, E., & Golde, T. E. (2001). Expression of BRI-amyloid β peptide fusion proteins: A novel method for specific high-level expression of amyloid β peptides. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1537(1), 58-62. https://doi.org/10.1016/S0925-4439(01)00054-0

@article{b6fdc946841248078979c2096a80c96e,

title = "Expression of BRI-amyloid β peptide fusion proteins: A novel method for specific high-level expression of amyloid β peptides",

abstract = "In order to develop transgenic animal models that selectively overexpress various Aβ peptides, we have developed a novel expression system that selectively expresses Aβ40 or Aβ42 in the secretory pathway. This system utilizes fusion constructs in which the sequence encoding the 23-amino-acid ABri peptide at the carboxyl terminus of the 266-amino-acid type 2 transmembrane protein BRI is replaced with a sequence encoding either Aβ40 or Aβ42. Constitutive processing of the resultant BRI-Aβ fusion proteins in transfected cells results in high-level expression and secretion of the encoded Aβ peptide. Significantly, expression of Aβ42 from the BRI-Aβ42 construct resulted in no increase in secreted Aβ40, suggesting that the majority of Aβ42 is not trimmed by carboxypeptidase to Aβ40 in the secretory pathway.",

keywords = "Alzheimer disease, Amyloid β protein, British familial dementia, Fusion proteins",

author = "Lewis, \{P. A.\} and S. Piper and M. Baker and L. Onstead and Murphy, \{M. P.\} and J. Hardy and R. Wang and E. McGowan and Golde, \{T. E.\}",

note = "Funding Information: This work was supported by a Beeson Award from AFAR, an Ellison Medical Foundation New Scholars award and the NIH (NS39072, T.E.G.) (AG10491, R.W.) (Mayo Clinic ADRC, J.H.). BC05, BAN50, and BA27 were gifts of Takeda Industries.",

year = "2001",

month = jul,

day = "27",

doi = "10.1016/S0925-4439(01)00054-0",

language = "English",

volume = "1537",

pages = "58--62",

number = "1",

}

TY - JOUR

T1 - Expression of BRI-amyloid β peptide fusion proteins

T2 - A novel method for specific high-level expression of amyloid β peptides

AU - Lewis, P. A.

AU - Piper, S.

AU - Baker, M.

AU - Onstead, L.

AU - Murphy, M. P.

AU - Hardy, J.

AU - Wang, R.

AU - McGowan, E.

AU - Golde, T. E.

N1 - Funding Information: This work was supported by a Beeson Award from AFAR, an Ellison Medical Foundation New Scholars award and the NIH (NS39072, T.E.G.) (AG10491, R.W.) (Mayo Clinic ADRC, J.H.). BC05, BAN50, and BA27 were gifts of Takeda Industries.

PY - 2001/7/27

Y1 - 2001/7/27

N2 - In order to develop transgenic animal models that selectively overexpress various Aβ peptides, we have developed a novel expression system that selectively expresses Aβ40 or Aβ42 in the secretory pathway. This system utilizes fusion constructs in which the sequence encoding the 23-amino-acid ABri peptide at the carboxyl terminus of the 266-amino-acid type 2 transmembrane protein BRI is replaced with a sequence encoding either Aβ40 or Aβ42. Constitutive processing of the resultant BRI-Aβ fusion proteins in transfected cells results in high-level expression and secretion of the encoded Aβ peptide. Significantly, expression of Aβ42 from the BRI-Aβ42 construct resulted in no increase in secreted Aβ40, suggesting that the majority of Aβ42 is not trimmed by carboxypeptidase to Aβ40 in the secretory pathway.

AB - In order to develop transgenic animal models that selectively overexpress various Aβ peptides, we have developed a novel expression system that selectively expresses Aβ40 or Aβ42 in the secretory pathway. This system utilizes fusion constructs in which the sequence encoding the 23-amino-acid ABri peptide at the carboxyl terminus of the 266-amino-acid type 2 transmembrane protein BRI is replaced with a sequence encoding either Aβ40 or Aβ42. Constitutive processing of the resultant BRI-Aβ fusion proteins in transfected cells results in high-level expression and secretion of the encoded Aβ peptide. Significantly, expression of Aβ42 from the BRI-Aβ42 construct resulted in no increase in secreted Aβ40, suggesting that the majority of Aβ42 is not trimmed by carboxypeptidase to Aβ40 in the secretory pathway.

KW - Alzheimer disease

KW - Amyloid β protein

KW - British familial dementia

KW - Fusion proteins

UR - http://www.scopus.com/inward/record.url?scp=0035958631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035958631&partnerID=8YFLogxK

U2 - 10.1016/S0925-4439(01)00054-0

DO - 10.1016/S0925-4439(01)00054-0

M3 - Article

C2 - 11476963

AN - SCOPUS:0035958631

SN - 0925-4439

VL - 1537

SP - 58

EP - 62

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

IS - 1

ER -

Expression of BRI-amyloid β peptide fusion proteins: A novel method for specific high-level expression of amyloid β peptides

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto